#801
Normal Gastrointestinal Neuroendocrine Cells Lack E-cadherin
Introduction:
E-cadherin plays a crucial role in the adhesion between epithelial cells and thus epithelial integrity. Moreover, germ line mutations in the E-cadherin gene (CDH1) causing loss of E-cadherin function (adhesion) leads to hereditary gastric cancer of the diffuse type, according to Laurén. Even sporadic gastric carcinomas of the diffuse type often lose E-cadherin expression due to mutations. Lack of E-cadherin has been recorded at an early phase in such carcinomas.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
Hauso �
Authors:
Hauso �,
Nordbø H,
Ringnes E,
Sørdal �,
Nordrum I,
Keywords:
E-cadherin,
neuroendocrine cell,
gastric cancer,
adhesion molecules,
neuroendocrine tumors,
carcinoid,
#622
Evaluation of Mucin and Neuroendocrine Expression in Diffuse Gastric Cancer with Signet Ring Cell Morphology
Introduction:
A proportion of diffuse gastric carcinoma, according to the Lauren classification system, has signet ring cell morphology. Signet ring cells are characterized by a peripherally placed nucleus and a central amorphous substance, which is reported to be mucin based on Periodic Acid Schiff positivity (PAS). PAS is not a specific staining method for mucin. Neuroendocrine expression has previously been reported in tumor cells in diffuse type gastric cancer.
Conference:
10th Annual ENETSConcerence (2013)
Presenting Author:
Sørdal �
Authors:
Sørdal �,
Qvigstad G,
Nordrum I,
Waldum H,
Keywords:
gastric signet ring cell carcinoma,
mucin,
neuroendocrine markers,
PAS,
#406
YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids
Introduction:
Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Conference:
9th Annual ENETSConcerence (2012)
Presenting Author:
Authors:
Fossmark R,
Sørdal �,
Jianu C,
Qvigstad G,
Boyce M,
Keywords:
gastric carcinoids,
gastrin,
chromogranin A,
